Nectar Lifesciences Limited has informed the Exchange regarding outcome of Board meeting held on May 30, 2025 regarding the Change in Directorate.The Audit Committee and Board of Directors could not approve and take on record the Audited Financial Results and Financial Statements for the quarter and year ended March 31, 2025. Therefore, the meetings stand adjourned sine die, for said matters. The reasons for delay in submission of financial results is being submitted by way of separate letter
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
At a Board meeting held on May 30, 2025, the Audit Committee and Board of Directors of Nectar Lifesciences could not approve the Audited Financial Results and Financial Statements for the quarter and year ended March 31, 2025. The meetings have been adjourned sine die (indefinitely) for these matters, meaning no new date has been fixed to revisit the approval. The company has stated that the reasons for the delay in submitting the financial results will be communicated separately to the exchange. This is a significant compliance lapse, as listed companies are required to file audited annual results within 45 days of the financial year-end, and the May 30 deadline was the final permissible date for FY25 results.
This is a serious negative signal for shareholders. Failure to approve audited results raises red flags about possible internal disputes, audit-related issues, or governance concerns, and could invite regulatory scrutiny from SEBI/NSE. Investors should watch for the company's separate explanation letter and any potential trading restrictions on the stock until results are filed.